Congenital insensitivity to pain (CIP) is a rare autosomal recessive disorder presenting with a spectrum of clinical features caused by mutations in different genes. A 10-year-old girl with CIP, hyposmia and hypogeusia, and her unaffected twin and parents underwent next generation sequencing of SCN9A exons and flanking splice sites. Transcript analysis from whole blood successfully assayed the effect of the mutation on the mRNA splicing by polymerase chain reaction amplification on cDNA and Sanger sequencing. We identified the novel splicing variant c.1108-2A>G compound with the p.Arg896Gln (c.2687G>A) missense mutation previously described in a homozygous patient. The new intronic variant was predicted to induce exon 10 skipping. Conversely, SCN9A mRNA assay demonstrated its partial deletion with a loss of 46 nucleotides causing a premature stop codon in position p.Gln369 (NP_002968). Genetic analysis showed that the two variants were biallelic, being the mother and brother heterozygous carriers of the missense mutation, and the father heterozygous for the splicing mutation. Skin biopsy showed lack of Meissner's corpuscles, loss of epidermal nociceptors and normal autonomic organ innervation. We report a novel splicing mutation and provide clues on its pathogenic effect, broadening the spectrum of genotypes and phenotypes associated to CIP.
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K E Y W O R D S
congenital insensitivity to pain, skin biopsy, small fiber neuropathy, sodium channel genes essential for pain sensing have been described are patients harboring party different phenotypes. 1 The first description of a person who apparently did not feel any pain except headache was published in 1932. 2 More structured clinical descriptions, including anhydrosis and mental retardation, date back to the 1950s' of the 20th century, 3 about 50 years before the discovery of the first causative mutations in NTRK1, the gene encoding a tyrosine receptor for nerve growth factor. 4 The syndrome was classified as hereditary sensory and autonomic neuropathy (HSAN) type IV or CIP and anhydrosis (OMIM: 256800), and the role of NTRK1 was later elucidated. 5 
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A small number of inactivating mutations in SCN9A have been published and, among these, truncating variants due to nonsense mutations or small ins/del represents the majority. We describe, providing evidence of the pathogenic effect and pathological details widening the phenotype, a novel splicing mutation biallelic to a known missense mutation in SCN9A found in a young patient with pain insensitivity and hyposmia.
2 | METHODS
| Clinical picture
The proband was a young girl born pre-term at the 36th week of preg- 
| DISCUSSION
We reported a new SCN9A splicing mutation in a compound heterozygous young patient presenting with CIP, hyposmia, and hypogeusia.
The clinical features resembled those observed in the majority of patients previously reported as affected by loss-of-function SCN9A FIGURE 1 A, Shows the normally dense and homogeneous pattern of sweat drop imprints obtained in the patients after pilocarpine stimulation by dynamic sweat test. Consistently, B shows the normal pattern of sweat gland innervation by post-ganglionic sudomotor nerves. Confocal micrographs of glabrous (C, D) and hairy (E, F) skin biopsy sections from the patient (C, E) and an age-matched healthy subject (D, F). In C, note the complete lack of Meissner corpuscles and in E the severe reduction of intraepidermal nerve fiber density, compared to D and F, respectively. In green, nerve fibers marked with the pan neuronal marker protein-gene-product 9.5; in red, blood vessels and basement membranes marked with collagen IV; in blue, endothelia and keratinocytes marked with ULEX europaeus. Scale bar equals 100 μm mutations. Indeed, our patient showed normal intelligence and autonomic functions, and had no dysmorphisms.
The missense mutation p.Arg896Gln localizes in the transmembrane region that delimits the channel pore in the second domain (S5-S6/DII). It was previously identified in a homozygous CIP patient from consanguineous Bedouin parents and reported to have to a lossof-function effect on the protein. 8 This study highlighted the importance of the aminoacid sequence delimiting the pore region, which is highly conserved between orthologous and paralogous genes, not only for the electrophysiological properties of the channel, but also for its correct folding and surface localization. Recently, this variant has been reported in dbSNP (rs1024152367) with a minor allele frequency of 8 x 10 −6 (www.ncbi.nlm.nih.gov/projects/SNP).
The novel intronic variant c.1108-2A>G found in our patient was Albeit overlapping, some phenotypic features might address the molecular diagnosis of CIP patients who, however, should be tested for all known genes when using next generation sequencing approach.
SCN9A inactivating mutations should be searched in patients with anosmia, normal intelligence and normal 17 or mildly abnormal 18 large sensory nerve fiber function. In patients with normal intelligence showing a pattern of pain insensitivity restricted to the limbs rather than diffuse and no anosmia, mutations in PRDM12 should be considered. 21 CIP patients with normal intelligence, hyperhidrosis, gastrointestinal dysfunction and mild muscular weakness, without anosmia, neuropathy, or cardiovascular dysautonomia could harbor SCN11A mutations. 20 When CIP is associated with impaired cognitive development and anhydrosis, the underlying molecular defect could be in the NTRK1 gene. 5 We have identified and characterized a new molecular defect of SCN9A in a young patient with CIP, hyposmia and hypogeusia that widens the spectrum of Nav1.7 impairments underlying this phenotype, and have demonstrated the effect of the mutation on whole blood transcript assay.
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